/
CYCN
$3.36-$0.02 (-0.74%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$14.6M
4M shares
52-week range
$1.03 – $8.48
31% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
134.29%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-74.64
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $4.5M | $2.3M | $3.3M | $297.0K | $0 | $2.0M | $2.1M |
| Cost of revenue | $1.5M | $95.1M | $56.4M | $0 | $5.6M | $0 | $0 | $0 |
| Gross profit | −$1.5M | −$90.6M | −$54.1M | $3.3M | −$5.3M | $0 | $2.0M | $2.1M |
| Gross margin | — | -2010.9% | -2357.1% | 100.0% | -1778.5% | — | 100.0% | 100.0% |
| R&D | $87.7M | $95.1M | $56.4M | $37.6M | $6.0M | $1.5M | $286.0K | $959.0K |
| Operating income | −$115.3M | −$125.0M | −$81.3M | −$55.2M | −$18.5M | −$13.0M | −$3.6M | −$5.0M |
| EBITDA | −$113.7M | −$122.3M | −$80.6M | −$53.8M | −$18.2M | −$9.6M | −$3.1M | −$3.5M |
| Net income | −$115.3M | −$123.0M | −$77.8M | −$51.6M | −$44.1M | −$5.3M | −$3.1M | −$3.5M |
| Net margin | — | -2729.3% | -3388.6% | -1555.6% | -14841.1% | — | -152.8% | -170.1% |
| EPS (diluted) | -84.42 | -88.37 | -47.80 | -26.40 | -20.15 | -8.99 | -1.21 | -1.09 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $90M | $-1.20 | $-1.20–$-1.20 | 1 |
| 2027 | $586141 | $-0.99 | $-0.99–$-0.99 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.96
Price
$3.35
Implied downside
-71%
Peer comparison
Cyclerion Therapeutics, Inc. Common Stock
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
www.cyclerion.com- Employees
- 1
- IPO / List date
- Mar 18, 2019
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds CYCN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-12-31 | 10,611 | $34.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-05-16 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded CYCN yet.
